Applied Genetic Technologies Corp (AGTC): Mark S Shearman , Chief Scientific Officer of Applied Genetic Technologies Corp purchased 3,000 shares on Sep 22, 2016. The Insider buying transaction was reported by the company on Sep 26, 2016 to the Securities and Exchange Commission. The shares were purchased at $8.87 per share for a total value of $26,601.50 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Sep 20, 2016, Lawrence E Bullock (CFO) purchased 10,000 shares at $8.75 per share price.On Feb 24, 2015, Plc Glaxosmithkline (other) sold 503,150 shares at $22.00 per share price.Also, On Jan 26, 2015, Daniel L Menichella (V.P. & Chief Business Officer) sold 1,996 shares at $24.90 per share price.
Applied Genetic Technologies Corp (AGTC) witnessed a volatile trading activity on Thursday Sep 22, 2016 and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $9 and reached the intraday high at $9.05. The bulls started the profit booking and pushed the shares to intraday low of $8.75. The trading session was marked by a volume range of 1,49,036 shares exchanging hands. The 52-week high of the shares is $21.43 and the 52-week low is $8.5. The market cap of the company stands at $160 M and there are 1,80,53,284 shares in public circulation.
Company has been under the radar of several Street Analysts.Applied Genetic Technologies Corp is Reiterated by Wedbush to Outperform while Lowering the Price Target of the company shares to $ 20 from a previous price target of $36 . The Rating was issued on Sep 13, 2016.Applied Genetic Technologies Corp is Reiterated by Stifel to Buy while Lowering the Price Target of the company shares to $ 24 from a previous price target of $29 . The Rating was issued on Sep 13, 2016.Applied Genetic Technologies Corp is Downgraded by Cantor Fitzgerald to Hold. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on Sep 13, 2016.Applied Genetic Technologies Corp is Downgraded by Wells Fargo to Market Perform. Earlier the firm had a rating of Outperform on the company shares. The Rating was issued on Sep 13, 2016.Applied Genetic Technologies Corp is Downgraded by ROTH Capital to Neutral. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on Sep 13, 2016.
Applied Genetic Technologies Corp is a United States-based clinical stage biotechnology company. The Company develops gene therapy products for the treatment of inherited and acquired diseases. Its products are used to treat Alpha One Antitrypsin Deficiency (Alpha-1) a respiratory disease caused by deficiencies in the tissue protective protein alpha one antitrypsin; and Lebers congenital amaurosis an inherited condition causing early blindness. Its products also used to treat X-linked retinoschisis an inherited form of retinal degeneration affecting young males with poor vision either in infancy or at school age; and achromatopsia an inherited condition that is associated with color blindness visual acuity loss and extreme light sensitivity resulting in daytime blindness.